Brief: Valneva Receives EMA’s Positive CHMP Opinion for Adolescent Label Extension for Chikungunya Vaccine IXCHIQ
28/02/2025 16:53
Feb 28 (Reuters) - Valneva SE VLS.PA: EXPECTS BRAZIL MARKETING APPROVAL IN Q1 2025 IXCHIQ TO BECOME FIRST CHIKUNGUNYA VACCINE FOR EU ADOLESCENTS EC DECISION ON IXCHIQ VACCINE INDICATION EXPECTED WITHIN 60 DAYS CHMP RECOMMENDS LABEL EXTENSION FOR VALNEVA'S CHIKUNGUNYA VACCINE TO ADOLESCENTS SIGNS EXCLUSIVE LICENSE AGREEMENT WITH SERUM INSTITUTE OF INDIA Source text: ID:nGNE82cTH3 Further company coverage: VLS.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48587696600;;))
Recent news on Valneva SE
See all newsBrief: UK MHRA Withdraws Marketing Authorisation for Ixchiq Chikungunya Vaccine After Safety Review
Valneva falls as UK regulator revokes Ixchiq vaccine authorisation
Brief: Valneva Provides Update On Ixchiq® In The United Kingdom
Valneva surges after EU regulator validates Lyme disease vaccine application
Brief: Pfizer And Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated By European Medicines Agency